Back to resultsDurvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)
Primary Purpose
Muscle Invasive Bladder Cancer
Status
Active
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Durvalumab
Cisplatin
Gemcitabine
Sponsored by
About this trial
This is an interventional treatment trial for Muscle Invasive Bladder Cancer focused on measuring Bladder Cancer, Immunotherapy, PD-L1, Durvalumab (MEDI4736)
Eligibility Criteria
Inclusion:
- Patient resectable muscle-invasive bladder cancer with clinical stage T2-T4aN0/1M0 with transitional and mixed transitional cell histology
- Patients must be planning to undergo a radical cystectomy
- Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC
- ECOG performance status of 0 or 1
- Must have a life expectancy of at least 12 weeks at randomization
Exclusion:
- Evidence of lymph node (N2-N3) or metastatic (M1) disease at time of screening.
- Prior pelvic radiotherapy treatment within 2 years of randomization to study
- Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin [BCG]), including but not limited to other anti-CTLA-4, anti-PD-1, anti PD-L1, or anti-PD-L2 antibodies.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product (IP). The following are exceptions to this criterion: Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection); Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent; Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
- Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
- Uncontrolled intercurrent illness
- Active infection including Tuberculosis, Hepatitis B, Hepatitis C, and Human Immunodeficiency
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Arm 1
Arm 2
Arm Description
Chemotherapy + Durvalumab
Chemotherapy alone
Outcomes
Primary Outcome Measures
Pathologic complete response (pCR) rates at time of cystectomy
Event-free survival (EFS) per central review defined as time from randomization to event
Secondary Outcome Measures
Proportion of patients who achieve <P2 at time of cystectomy
EFS at 24 months (EFS24) defined as time from randomization to event
Proportion of patients who undergo cystectomy
Overall survival rate at 5 years
PFS2 defined as time from randomization to event following subsequent therapy
Safety and Tolerability as evaluated by adverse events occurring throughout the study
Immunogenicity of durvalumab when used in combination with gemcitabine/cisplatin as measured by presence of antidrug antibodies (ADA)
Overall Survival
Metastasis-free survival per investigator assessment or local biopsy review.
Disease-specific survival per investigator assessment or local biopsy review.
Disease-free survival
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03732677
Brief Title
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
Acronym
NIAGARA
Official Title
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 16, 2018 (Actual)
Primary Completion Date
June 30, 2025 (Anticipated)
Study Completion Date
June 30, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Muscle Invasive Bladder Cancer
Keywords
Bladder Cancer, Immunotherapy, PD-L1, Durvalumab (MEDI4736)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1063 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm 1
Arm Type
Experimental
Arm Description
Chemotherapy + Durvalumab
Arm Title
Arm 2
Arm Type
Active Comparator
Arm Description
Chemotherapy alone
Intervention Type
Drug
Intervention Name(s)
Durvalumab
Intervention Description
Anti- PD-L1 Antibody
Intervention Type
Drug
Intervention Name(s)
Cisplatin
Intervention Description
Chemotherapy Agent
Intervention Type
Drug
Intervention Name(s)
Gemcitabine
Intervention Description
Chemotherapy agent
Primary Outcome Measure Information:
Title
Pathologic complete response (pCR) rates at time of cystectomy
Time Frame
Up to 6 months
Title
Event-free survival (EFS) per central review defined as time from randomization to event
Time Frame
Up to 48 months
Secondary Outcome Measure Information:
Title
Proportion of patients who achieve <P2 at time of cystectomy
Time Frame
Up to 6 months
Title
EFS at 24 months (EFS24) defined as time from randomization to event
Time Frame
Up to 24 months
Title
Proportion of patients who undergo cystectomy
Time Frame
Up to 6 months
Title
Overall survival rate at 5 years
Time Frame
Up to 60 months
Title
PFS2 defined as time from randomization to event following subsequent therapy
Time Frame
Up to 84 months
Title
Safety and Tolerability as evaluated by adverse events occurring throughout the study
Time Frame
Up to 84 months
Title
Immunogenicity of durvalumab when used in combination with gemcitabine/cisplatin as measured by presence of antidrug antibodies (ADA)
Time Frame
Up to 12 months
Title
Overall Survival
Time Frame
Up to 84 months
Title
Metastasis-free survival per investigator assessment or local biopsy review.
Time Frame
Up to 48 months
Title
Disease-specific survival per investigator assessment or local biopsy review.
Time Frame
up to 48 months
Title
Disease-free survival
Time Frame
Up to 48 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
130 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion:
Patient resectable muscle-invasive bladder cancer with clinical stage T2-T4aN0/1M0 with transitional and mixed transitional cell histology
Patients must be planning to undergo a radical cystectomy
Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC
ECOG performance status of 0 or 1
Must have a life expectancy of at least 12 weeks at randomization
Exclusion:
Evidence of lymph node (N2-N3) or metastatic (M1) disease at time of screening.
Prior pelvic radiotherapy treatment within 2 years of randomization to study
Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin [BCG]), including but not limited to other anti-CTLA-4, anti-PD-1, anti PD-L1, or anti-PD-L2 antibodies.
Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product (IP). The following are exceptions to this criterion: Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection); Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent; Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
Uncontrolled intercurrent illness
Active infection including Tuberculosis, Hepatitis B, Hepatitis C, and Human Immunodeficiency
Facility Information:
Facility Name
Research Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Research Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Research Site
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Facility Name
Research Site
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
Research Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Research Site
City
Geneva
State/Province
Illinois
ZIP/Postal Code
60134
Country
United States
Facility Name
Research Site
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
Research Site
City
Westwood
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Facility Name
Research Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Research Site
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Facility Name
Research Site
City
Towson
State/Province
Maryland
ZIP/Postal Code
21204
Country
United States
Facility Name
Research Site
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Research Site
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
Research Site
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Research Site
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Research Site
City
Bethlehem
State/Province
Pennsylvania
ZIP/Postal Code
18015
Country
United States
Facility Name
Research Site
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Facility Name
Research Site
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
Research Site
City
Brisbane
ZIP/Postal Code
4122
Country
Australia
Facility Name
Research Site
City
Elizabeth Vale
ZIP/Postal Code
5112
Country
Australia
Facility Name
Research Site
City
Macquarie University
ZIP/Postal Code
2109
Country
Australia
Facility Name
Research Site
City
Melbourne
ZIP/Postal Code
3004
Country
Australia
Facility Name
Research Site
City
Murdoch
ZIP/Postal Code
6150
Country
Australia
Facility Name
Research Site
City
South Brisbane
ZIP/Postal Code
4101
Country
Australia
Facility Name
Research Site
City
Brugge
ZIP/Postal Code
8000
Country
Belgium
Facility Name
Research Site
City
Charleroi
ZIP/Postal Code
6000
Country
Belgium
Facility Name
Research Site
City
Kortrijk
ZIP/Postal Code
8500
Country
Belgium
Facility Name
Research Site
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Research Site
City
Liège
ZIP/Postal Code
4000
Country
Belgium
Facility Name
Research Site
City
Roeselare
ZIP/Postal Code
8800
Country
Belgium
Facility Name
Research Site
City
Barretos
ZIP/Postal Code
14784-400
Country
Brazil
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90020-090
Country
Brazil
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90470-340
Country
Brazil
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
91350-200
Country
Brazil
Facility Name
Research Site
City
Rio de Janeiro
ZIP/Postal Code
20231-050
Country
Brazil
Facility Name
Research Site
City
Santa Maria
ZIP/Postal Code
97015-450
Country
Brazil
Facility Name
Research Site
City
Sao Paulo
ZIP/Postal Code
01323-903
Country
Brazil
Facility Name
Research Site
City
Sao Paulo
ZIP/Postal Code
01509-900
Country
Brazil
Facility Name
Research Site
City
São José do Rio Preto
ZIP/Postal Code
15090-000
Country
Brazil
Facility Name
Research Site
City
São Paulo
ZIP/Postal Code
01246-000
Country
Brazil
Facility Name
Research Site
City
São Paulo
ZIP/Postal Code
03102-002
Country
Brazil
Facility Name
Research Site
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
Facility Name
Research Site
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E6
Country
Canada
Facility Name
Research Site
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5W9
Country
Canada
Facility Name
Research Site
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Facility Name
Research Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G IX6
Country
Canada
Facility Name
Research Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2X 0C2
Country
Canada
Facility Name
Research Site
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 5N4
Country
Canada
Facility Name
Research Site
City
Antofagasta
ZIP/Postal Code
1267348
Country
Chile
Facility Name
Research Site
City
Puerto Montt
ZIP/Postal Code
5480000
Country
Chile
Facility Name
Research Site
City
Santiago
ZIP/Postal Code
7520349
Country
Chile
Facility Name
Research Site
City
Temuco
ZIP/Postal Code
4810218
Country
Chile
Facility Name
Research Site
City
Temuco
ZIP/Postal Code
4810469
Country
Chile
Facility Name
Research Site
City
Viña del Mar
ZIP/Postal Code
2540488
Country
Chile
Facility Name
Research Site
City
Brno
ZIP/Postal Code
656 53
Country
Czechia
Facility Name
Research Site
City
Brno
ZIP/Postal Code
656 91
Country
Czechia
Facility Name
Research Site
City
Hradec Kralove
ZIP/Postal Code
500 05
Country
Czechia
Facility Name
Research Site
City
Olomouc
ZIP/Postal Code
77900
Country
Czechia
Facility Name
Research Site
City
Praha 2
ZIP/Postal Code
128 08
Country
Czechia
Facility Name
Research Site
City
Praha 8
ZIP/Postal Code
180 81
Country
Czechia
Facility Name
Research Site
City
Praha
ZIP/Postal Code
140 59
Country
Czechia
Facility Name
Research Site
City
Angers Cedex 01
ZIP/Postal Code
49033
Country
France
Facility Name
Research Site
City
Dijon
ZIP/Postal Code
21079
Country
France
Facility Name
Research Site
City
Grenoble Cedex 09
ZIP/Postal Code
38043
Country
France
Facility Name
Research Site
City
Montpellier
ZIP/Postal Code
34070
Country
France
Facility Name
Research Site
City
Nimes
ZIP/Postal Code
30029
Country
France
Facility Name
Research Site
City
Pierre Benite
ZIP/Postal Code
69495
Country
France
Facility Name
Research Site
City
Poitiers Cedex
ZIP/Postal Code
86021
Country
France
Facility Name
Research Site
City
Rouen
ZIP/Postal Code
F-76031 CE
Country
France
Facility Name
Research Site
City
Bergisch Gladbach
ZIP/Postal Code
51465
Country
Germany
Facility Name
Research Site
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Facility Name
Research Site
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Research Site
City
Göttingen
ZIP/Postal Code
37075
Country
Germany
Facility Name
Research Site
City
Herne
ZIP/Postal Code
44625
Country
Germany
Facility Name
Research Site
City
Jena
ZIP/Postal Code
07747
Country
Germany
Facility Name
Research Site
City
Köln
ZIP/Postal Code
50937
Country
Germany
Facility Name
Research Site
City
Magdeburg
ZIP/Postal Code
39120
Country
Germany
Facility Name
Research Site
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
Research Site
City
Münster
ZIP/Postal Code
48149
Country
Germany
Facility Name
Research Site
City
Nürnberg
ZIP/Postal Code
90491
Country
Germany
Facility Name
Research Site
City
Oldenburg
ZIP/Postal Code
23758
Country
Germany
Facility Name
Research Site
City
Regensburg
ZIP/Postal Code
93053
Country
Germany
Facility Name
Research Site
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Facility Name
Research Site
City
Würzburg
ZIP/Postal Code
97080
Country
Germany
Facility Name
Research Site
City
Haifa
ZIP/Postal Code
31096
Country
Israel
Facility Name
Research Site
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Facility Name
Research Site
City
Kfar Saba
ZIP/Postal Code
95847
Country
Israel
Facility Name
Research Site
City
Petach-Tikva
ZIP/Postal Code
4941492
Country
Israel
Facility Name
Research Site
City
Ramat Gan
ZIP/Postal Code
52621
Country
Israel
Facility Name
Research Site
City
Bari
ZIP/Postal Code
70124
Country
Italy
Facility Name
Research Site
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Facility Name
Research Site
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Facility Name
Research Site
City
Milano
ZIP/Postal Code
20132
Country
Italy
Facility Name
Research Site
City
Milano
ZIP/Postal Code
20133
Country
Italy
Facility Name
Research Site
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Facility Name
Research Site
City
Orbassano
ZIP/Postal Code
10043
Country
Italy
Facility Name
Research Site
City
Pozzuoli
ZIP/Postal Code
80078
Country
Italy
Facility Name
Research Site
City
Verona
ZIP/Postal Code
37126
Country
Italy
Facility Name
Research Site
City
Bunkyo-ku
ZIP/Postal Code
113-8603
Country
Japan
Facility Name
Research Site
City
Fukuoka-shi
ZIP/Postal Code
811-1347
Country
Japan
Facility Name
Research Site
City
Fukuoka
ZIP/Postal Code
812-8582
Country
Japan
Facility Name
Research Site
City
Hirosaki-shi
ZIP/Postal Code
036-8563
Country
Japan
Facility Name
Research Site
City
Hiroshima-shi
ZIP/Postal Code
730-8518
Country
Japan
Facility Name
Research Site
City
Kanazawa-shi
ZIP/Postal Code
920-8641
Country
Japan
Facility Name
Research Site
City
Koto-ku
ZIP/Postal Code
135-8550
Country
Japan
Facility Name
Research Site
City
Kumamoto-shi
ZIP/Postal Code
860-0008
Country
Japan
Facility Name
Research Site
City
Miyazaki-city
ZIP/Postal Code
889-1692
Country
Japan
Facility Name
Research Site
City
Nagasaki-shi
ZIP/Postal Code
852-8501
Country
Japan
Facility Name
Research Site
City
Nagoya-shi
ZIP/Postal Code
466-8560
Country
Japan
Facility Name
Research Site
City
Niigata-shi
ZIP/Postal Code
951-8520
Country
Japan
Facility Name
Research Site
City
Osaka-shi
ZIP/Postal Code
541-8567
Country
Japan
Facility Name
Research Site
City
Osaka-shi
ZIP/Postal Code
545-8586
Country
Japan
Facility Name
Research Site
City
Osakasayama-shi
ZIP/Postal Code
589-8511
Country
Japan
Facility Name
Research Site
City
Sendai-shi
ZIP/Postal Code
980-0872
Country
Japan
Facility Name
Research Site
City
Toyama-shi
ZIP/Postal Code
930-0194
Country
Japan
Facility Name
Research Site
City
Tsukuba-shi
ZIP/Postal Code
305-8576
Country
Japan
Facility Name
Research Site
City
Yokohama-shi
ZIP/Postal Code
232-0024
Country
Japan
Facility Name
Research Site
City
Yokohama-shi
ZIP/Postal Code
241-8515
Country
Japan
Facility Name
Research Site
City
Daegu
ZIP/Postal Code
41404
Country
Korea, Republic of
Facility Name
Research Site
City
Goyang-si
ZIP/Postal Code
10408
Country
Korea, Republic of
Facility Name
Research Site
City
Gyeonggi-do
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Research Site
City
Incheon
ZIP/Postal Code
21565
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
ZIP/Postal Code
136-705
Country
Korea, Republic of
Facility Name
Research Site
City
Amsterdam
ZIP/Postal Code
1066 CX
Country
Netherlands
Facility Name
Research Site
City
Amsterdam
ZIP/Postal Code
1081 HV
Country
Netherlands
Facility Name
Research Site
City
Breda
ZIP/Postal Code
4818 CK
Country
Netherlands
Facility Name
Research Site
City
Rotterdam
ZIP/Postal Code
3015 GD
Country
Netherlands
Facility Name
Research Site
City
Baguio City
ZIP/Postal Code
2600
Country
Philippines
Facility Name
Research Site
City
Cebu
ZIP/Postal Code
6000
Country
Philippines
Facility Name
Research Site
City
Davao City
ZIP/Postal Code
8000
Country
Philippines
Facility Name
Research Site
City
Makati
ZIP/Postal Code
1229
Country
Philippines
Facility Name
Research Site
City
Manila
ZIP/Postal Code
1015
Country
Philippines
Facility Name
Research Site
City
Quezon City
ZIP/Postal Code
1101
Country
Philippines
Facility Name
Research Site
City
Quezon City
ZIP/Postal Code
1104
Country
Philippines
Facility Name
Research Site
City
Bialystok
ZIP/Postal Code
15-027
Country
Poland
Facility Name
Research Site
City
Gdańsk
ZIP/Postal Code
80-214
Country
Poland
Facility Name
Research Site
City
Grudziądz
ZIP/Postal Code
86-300
Country
Poland
Facility Name
Research Site
City
Koszalin
ZIP/Postal Code
75-581
Country
Poland
Facility Name
Research Site
City
Kraków
ZIP/Postal Code
30-510
Country
Poland
Facility Name
Research Site
City
Olsztyn
ZIP/Postal Code
10-228
Country
Poland
Facility Name
Research Site
City
Ostrołęka
ZIP/Postal Code
07-410
Country
Poland
Facility Name
Research Site
City
Poznan
ZIP/Postal Code
60-693
Country
Poland
Facility Name
Research Site
City
Warszawa
ZIP/Postal Code
02-781
Country
Poland
Facility Name
Research Site
City
Wroclaw
ZIP/Postal Code
53-413
Country
Poland
Facility Name
Research Site
City
Krasnoyarsk
ZIP/Postal Code
660133
Country
Russian Federation
Facility Name
Research Site
City
Moscow
ZIP/Postal Code
105077
Country
Russian Federation
Facility Name
Research Site
City
Nizhniy Novgorod
ZIP/Postal Code
603074
Country
Russian Federation
Facility Name
Research Site
City
Novosibirsk
ZIP/Postal Code
630007
Country
Russian Federation
Facility Name
Research Site
City
Samara
ZIP/Postal Code
443031
Country
Russian Federation
Facility Name
Research Site
City
St Petersburg
ZIP/Postal Code
194044
Country
Russian Federation
Facility Name
Research Site
City
St. Petersburg
ZIP/Postal Code
194017
Country
Russian Federation
Facility Name
Research Site
City
St. Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
Facility Name
Research Site
City
St. Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Facility Name
Research Site
City
Ufa
ZIP/Postal Code
450000
Country
Russian Federation
Facility Name
Research Site
City
Vologda
ZIP/Postal Code
160012
Country
Russian Federation
Facility Name
Research Site
City
Badalona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Research Site
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Research Site
City
Córdoba
ZIP/Postal Code
14004
Country
Spain
Facility Name
Research Site
City
Las Palmas de Gran Canaria
ZIP/Postal Code
35016
Country
Spain
Facility Name
Research Site
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Research Site
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Research Site
City
Santander
ZIP/Postal Code
39008
Country
Spain
Facility Name
Research Site
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Facility Name
Research Site
City
Kaohsiung
ZIP/Postal Code
807
Country
Taiwan
Facility Name
Research Site
City
Taichung
ZIP/Postal Code
404
Country
Taiwan
Facility Name
Research Site
City
Taichung
ZIP/Postal Code
40705
Country
Taiwan
Facility Name
Research Site
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Facility Name
Research Site
City
Tainan
ZIP/Postal Code
710
Country
Taiwan
Facility Name
Research Site
City
Taipei City
ZIP/Postal Code
10050
Country
Taiwan
Facility Name
Research Site
City
Taipei
ZIP/Postal Code
11217
Country
Taiwan
Facility Name
Research Site
City
Taoyuan City
ZIP/Postal Code
333
Country
Taiwan
Facility Name
Research Site
City
Ankara
ZIP/Postal Code
06590
Country
Turkey
Facility Name
Research Site
City
Edirne
ZIP/Postal Code
22030
Country
Turkey
Facility Name
Research Site
City
Istanbul
ZIP/Postal Code
34030
Country
Turkey
Facility Name
Research Site
City
İstanbul
ZIP/Postal Code
34457
Country
Turkey
Facility Name
Research Site
City
Izmir
Country
Turkey
Facility Name
Research Site
City
Karsiyaka
ZIP/Postal Code
35575
Country
Turkey
Facility Name
Research Site
City
Edinburgh
ZIP/Postal Code
EH4 2XR
Country
United Kingdom
Facility Name
Research Site
City
London
ZIP/Postal Code
E1 1BB
Country
United Kingdom
Facility Name
Research Site
City
Nottingham
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Facility Name
Research Site
City
Sheffield
ZIP/Postal Code
S10 2SJ
Country
United Kingdom
Facility Name
Research Site
City
Wirral
ZIP/Postal Code
CH63 4JY
Country
United Kingdom
Facility Name
Research Site
City
Hanoi
ZIP/Postal Code
100000
Country
Vietnam
Facility Name
Research Site
City
Ho Chi Minh
ZIP/Postal Code
700000
Country
Vietnam
Facility Name
Research Site
City
Hochiminh
ZIP/Postal Code
70000
Country
Vietnam
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing URL
https://astrazenecagroup-dt.pharmacm.com/DT/Home
Learn more about this trial
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
We'll reach out to this number within 24 hrs